Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma.
Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the patient-reported outcome (PRO) data from the phase 3 TRANSFORM study (NCT03575351) in relapsed/ refractory large B-cell lymphoma (LBCL).
The trial compared standard of care high-dose chemotherapy with lisocabtagene maraleucel (liso-cel; Breyanzi) in the second-line setting in patients with relapsed/refractory LBCL, Westin said. Moreover, this study was important because it observed what the experience of the patients on the trial was, including levels of fatigue, pain, and cognitive function, Westin explains. The data from the study showed that patients had improved response rates and quality of life with liso-cel vs high-dose chemotherapy followed by autologous stem cell transplant, Westin explained.
Although some outcomes were more problematic for patients with CAR T-cell therapy vs chemotherapy, many aspects of care including the patient's perception of their overall health, their functionality, and their fatigue levels, appeared to be more favorable with CAR T-cell therapy vs chemotherapy, Westin says.
Overall, these redults suggest that standard of care options in the second-line setting may be shifting away from high-dose chemotherapy over to CAR T-cell therapy, Westin concludes.